High blood sugar levels but not diabetes mellitus significantlyenhance oxaliplatin chemoresistance in patients with stage III colorectal cancerreceiving adjuvant FOLFOX6 chemotherapy

摘要

Background:The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection. However, chemotherapy resistance is associated with a poor prognosis. The prognostic impact of high blood sugar levels on oxaliplatin resistance in CRC patients is an unexplored topic.